| Literature DB >> 32312325 |
Carla Maia1,2, José Cristóvão3,4, André Pereira3,4, Tatiana Kostalova5, Tereza Lestinova5, Petra Sumova5, Petr Volf5, Lenea Campino4.
Abstract
BACKGROUND: In endemic areas of zoonotic leishmaniosis caused by L. infantum, early detection of Leishmania infection in dogs is essential to control the dissemination of the parasite to humans. The aim of this study was to evaluate the serological and/or molecular diagnostic performance of minimally and non-invasive samples (conjunctiva cells (CS) and peripheral blood (PB)) for monitoring Leishmania infection/exposure to Phlebotomus perniciosus salivary antigens in dogs at the beginning and the end of sand fly seasonal activity (May and October, respectively) and to assess associated risks factors.Entities:
Keywords: Blood; Conjunctival cells; Dog; Exposure; L. infantum; Phlebotomus pernicious; Saliva
Mesh:
Substances:
Year: 2020 PMID: 32312325 PMCID: PMC7171869 DOI: 10.1186/s13071-020-3993-7
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Combined results of the serological and molecular analyses performed to assess the contact of kennelled dogs to Leishmania parasites at the beginning and end of sand fly season
| Diagnostic test | Sand fly season ( | ||||
|---|---|---|---|---|---|
| ELISA | IFAT | Peripheral blood PCR | Conjunctival swab PCRa | Start, | End, |
| − | − | − | − | 111 (53.4) | 92 (44.2) |
| − | − | − | + | 0 (0) | 47 (22.6) |
| − | − | + | − | 71 (34.1) | 24 (11.5) |
| − | + | − | − | 0 (0) | 0 (0) |
| + | − | − | − | 4 (1.9) | 5 (2.4) |
| − | − | + | + | 0 (0) | 15 (7.2) |
| − | + | − | + | 0 (0) | 1 (0.5) |
| − | + | + | − | 0 (0) | 0 (0) |
| + | − | − | + | 0 (0) | 4 (1.9) |
| + | − | + | − | 8 (3.8) | 0 (0) |
| + | + | − | − | 8 (3.8) | 9 (4.3) |
| − | + | + | + | 0 (0) | 0 (0) |
| + | + | + | − | 6 2.9) | 6 (2.9) |
| + | + | − | + | 0 (0) | 4 (1.9) |
| + | − | + | + | 0 (0) | 1 (0.5) |
| + | + | + | + | 0 (0) | 0 (0) |
aAll negative at the beginning of the sand fly season
Abbreviations: ELISA, enzyme-linked immunosorbent assay; IFAT, immunofluorescence antibody test; PCR, polymerase chain reaction
Contact of kennelled dogs to Leishmania parasites at the beginning and end of sand fly season—prevalence, cumulative incidence and relative risk factors by diagnostic test
| Variable/category | Diagnostic test | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELISA | IFAT | Peripheral blood PCR | Conjunctival swab PCR | |||||||||||||
| P1 | P2 | I | RR (95% CI) | P1 | P2 | I | RR (95% CI) | P1 | P2 | I | RR (95% CI) | P1 | P2 | I | RR (95% CI) | |
| Sex, | ||||||||||||||||
| Femaleh | 12 (9.8) | 13 (10.6) | 2 (3.0) | 6 (4.9) | 9 (7.3) | 1 (1.5) | 52 (42.3) | 30 (24.4) | 19 (28.8) | 0 (0) | 45 (36.6) | 21 (31.8) | ||||
| Male | 14 (16.5) | 16 (18.8) | 3 (6.7) | 2.20 (0.38–12.64) | 8 (9.4) | 11 (12.9) | 1 (2.2) | 1.47 (0.09–22.85) | 33 (38.8) | 16 (18.8) | 8 (17.8) | 0.62 (0.30–1.29) | 0 (0) | 27 (31.8) | 15 (33.3) | 1.05 (0.61–1.8) |
| Age group, | 0.21 (0.02–2.97) | |||||||||||||||
| < 1 yearh | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||
| 1–7 years | 13 (10.0) | 17 (13.1) | 3 (3.9) | Infinity | 9 (6.9) | 13 (10.0) | 1 (1.3) | Infinity | 47 (36.2) | 26 (20.0) | 17 (22.1) | Infinity | 0 (0) | 44 (33.8) | 23 (29.9) | Infinity |
| > 7 years | 11 (17.2) | 10 (15.6) | 2 (7.1) | Infinity | 3 (4.7) | 5 (7.8) | 1 (3.6) | Infinity | 31 (48.4) | 13 (20.3) | 7 (25.0) | Infinity | 0 (0) | 20 (31.3) | 8 (28.6) | Infinity |
| Breed, | ||||||||||||||||
| Mongrelh | 15 (9.4)d | 19 (11.9) | 3 (3.4) | 8 (5.0) | 12 (7.5) | 1 (1.1) | 65 (40.9) | 31 (19.5) | 19 (21.8) | 0 (0) | 51 (32.1) | 26 (29.9) | ||||
| Crossed | 3 (14.3) | 4 (19.0) | 2 (18.2) | 5.27 (0.99–28.17) | 2 (9.5) | 3 (14.3) | 1 (9.1) | 7.91 (0.53–117.7) | 8 (38.1) | 5 (23.8) | 3 (27.3) | 1.25 (0.44–3.55) | 0 (0) | 10 (47.6) | 4 (36.4) | 1.22 (0.52–2.83) |
| Pure | 8 (28.6)d | 6 (21.4) | 0 (0) | 0 | 4 (14.3) | 5 (17.9) | 0 (0) | 0 | 12 (42.9) | 10 (35.7) | 5 (38.5) | 1.76 (0.80–3.90) | 0 (0) | 11 (39.3) | 6 (46.2) | 2.01 (0.62–6.57) |
| Coat length, | ||||||||||||||||
| Shorth | 15 (11.0) | 18 (13.2) | 2 (2.7) | 8 (5.9) | 11 (8.1) | 0 (0) | 55 (40.4) | 28 (20.6) | 16 (21.6) | 0 (0) | 47 (34.6) | 22 (29.7) | ||||
| Medium or long | 10 (14.5) | 10 (14.5) | 3 (8.3) | 3.08 (0.54–17.64) | 5 (7.2) | 8 (11.6) | 2 (5.6) | Infinity | 29 (42.0) | 17 (24.6) | 11 (30.6) | 1.41 (0.73–2.72) | 0 (0) | 24 (34.8) | 13 (36.1) | 1.22 (0.70–2.12) |
| Coat colour, | ||||||||||||||||
| Brighth | 4 (8.0) | 7 (14.0) | 2 (6.7) | 4 (8.0) | 4 (8.0) | 1 (3.3) | 17 (34.0) | 15 (30.0)e | 9 (30.0) | 0 (0) | 23 (46.0) | 15 (50.0) | ||||
| Mix | 12 (12.6) | 12 (12.6) | 1 (2.0) | 0.31 (0.03–3.23) | 5 (5.3) | 7 (7.4) | 0 (0) | 0 | 40 (42.1) | 13 (13.7)e,f | 8 (16.3) | 0.54 (0.24–1.26) | 0 (0) | 33 (34.7) | 15 (30.6)g | 0.61 (0.35–1.06) |
| Dark | 9 (15.8) | 9 (15.8) | 2 (6.5) | 0.97 (0.15–6.43) | 5 (8.8) | 8 (14.0) | 1 (3.2) | 0.97 (0.06–14.78) | 23 (40.4) | 18 (31.6)f | 10 (32.3) | 1.07 (0.51–2.27) | 0 (0) | 14 (24.6) | 6 (19.4)g | 0.39 (0.17–0.86) |
| Clinical signs | ||||||||||||||||
| Absenth | 15 (9.7) | 22 (11.8) | 3 (2.9) | 8 (5.2) | 16 (8.6) | 2 (1.9) | 67 (43.2) | 42 (22.5) | 26 (25.2) | 0 (0) | 63 (33.7) | 34 (33.0) | ||||
| Present | 11 (20.8) | 7 (33.3) | 2 (25.0) | 8.58 (1.67–44.17) | 6 (11.3) | 4 (19.0) | 0 (0) | 0 | 18 (34.0) | 4 (19.0) | 1 (12.5) | 0.50 (0.08–3.19) | 0 (0) | 9 (42.9) | 2 (25.0) | 0.76 (0.22–2.6) |
| Insecticides | ||||||||||||||||
| Noh | 23 (12.2) | 20 (11.8) | 3 (3.4) | 12 (6.4) | 13 (7.7) | 1 (1.1) | 78 (41.5) | 32 (18.9) | 17 (19.1) | 0 (0) | 58 (34.3) | 29 (32.6) | ||||
| Yes | 1 (5.6) | 9 (23.1) | 2 (9.1) | 2.7 (0.48–15.17) | 0 (0.0) | 7 (17.9) | 1 (4.5) | 4.04 (0.26–62.17) | 6 (33.3) | 14 (35.9) | 10 (45.5) | 2.38 (1.27–4.45) | 0 (0) | 14 (35.9) | 7 (31.8) | 0.98 (0.49–1.93) |
| Ac anti-rSP03B, | ||||||||||||||||
| Noh | 9 (11.4) | 4 (13.3) | 1 (6.3) | 4 (5.1) | 3 (10.0) | 1 (6.3) | 28 (35.4) | 11 (36.7) | 7 (43.8) | 0 (0) | 9 (30.0) | 3 (18.8) | ||||
| Yes | 17 (13.2) | 25 (14.0) | 4 (4.2) | 0.67 (0.08–5.65) | 10 (7.8) | 17 (9.6) | 1 (1.1) | 0.17 (0.01–2.56) | 57 (44.2) | 35 (19.7) | 20 (21.1) | 0.48 (0.24–0.95) | 0 (0) | 63 (35.4) | 33 (34.7) | 1.85 (0.64–5.33) |
| Ac anti-rSP03B + rSP01, | ||||||||||||||||
| Noh | 2 (5.9) | 4 (22.2) | 1 (14.3) | 1 (2.9) | 1 (5.6) | 0 (0) | 13 (38.2) | 5 (27.8) | 3 (42.9) | 0 (0) | 10 (55.6) | 3 (42.9) | ||||
| Yes | 24 (13.8) | 25 (13.2) | 4 (3.8) | 0.27 (0.04–2.10) | 13 (7.5) | 19 (10.0) | 2 (1.9) | Infinity | 72 (41.4) | 41 (21.6) | 24 (23.1) | 0.54 (0.21–1.36) | 0 (0) | 62 (32.6) | 33 (31.7) | 0.74 (0.30–1.82) |
| Ac anti-SGH, | ||||||||||||||||
| Noh | 4 (7.5) | 3 (11.5) | 1 (8.3) | 3 (5.7) | 1 (3.8) | 0 (0) | 16 (30.2) | 8 (30.8) | 4 (33.3) | 0 (0) | 11 (42.3) | 5 (41.7) | ||||
| Yes | 22 (14.2) | 26 (14.3) | 4 (4.0) | 0.48 (0.06–3.99) | 11 (7.1) | 19 (10.4) | 2 (2.0) | Infinity | 69 (44.5) | 38 (20.9) | 23 (23.2) | 0.7 (0.29–1.68) | 0 (0) | 61 (33.5) | 31 (31.3) | 0.75 (0.36–1.56) |
| Total, | 26 (12.5) | 29 (13.9) | 5 (4.5) | 14 (6.7) | 20 (9.6) | 2 (1.8) | 85 (40.9) | 46 (22.1) | 27 (24.3) | 0 (0) | 72 (34.6) | 36 (32.4) | ||||
aP1 and P2 (n = 195); I (n = 106)
bP1 and P2 (n = 205); I (n = 110)
cP1 and P2 (n = 202); I (n = 110)
dP = 0.019
eP = 0.018
fP = 0.008
gP = 0.012
hReference category
*Significant statistical association (α ≤ 0.05)
Abbreviations: ELISA, enzyme-linked immunosorbent assay; IFAT, immunofluorescence antibody test; PCR, polymerase chain reaction; P1, prevalence of Leishmania infection at the beginning of the sand fly season (n = 208); P2, prevalence of Leishmania infection at the end of the sand fly season (n = 208); I, cumulative incidence (n = 111); RR, relative risk; 95% CI, 95% confidence interval; rSP03B, 43 KDa yellow-related protein; rSP03B + rSP01, rSP03B and 35.5 kDa apyrase; SGH, salivary gland homogenate
Comparison of median levels of antibodies to Leishmania or Phlebotomus perniciosus at the beginning and end of the sand fly season
| Serological technique | Sand fly season ( | ||||
|---|---|---|---|---|---|
| Start | End | ||||
| Median (IQR) | Range | Median (IQR) | Range | ||
| ELISA-rSP03B | 0.350 (0.282–0.496) | 0.117–1.406 | 0.369 (0.280–0.491) | 0.143–1.066 | 0.793 |
| ELISA-rSP03B + rSP01 | 0.370 (0.292–0.508) | 0.129–1.253 | 0.393 (0.308–0.556) | 0.164–1.451 | 0.060 |
| ELISA-SGH | 0.237 (0.186–0.343) | 0.083–1.444 | 0.282 (0.232–0.380) | 0.110–1.404 | < 0.001 |
| ELISA | 0.037 (0.024–0.064) | 0.000–1.680 | 0.038 (0.025–0.071) | 0–1.620 | 0.457 |
| IFAT | 0 (0–0) | 0–2048 | 0 (0–0) | 0–9192 | 0.919 |
Abbreviations: ELISA, enzyme-linked immunosorbent assay; IFAT, immunofluorescence antibody test; rSP03B, 43 KDa yellow-related protein; rSP03B + rSP01, rSP03B and 35.5 kDa apyrase; SGH, salivary gland homogenate; IQR, interquartile interval (quartile 1–quartile 3)
Combined results of the serological analyses performed to assess the exposure of kennelled dogs to Phlebotomus perniciosus at the beginning and end of the sand fly season
| Salivary gland antigen | Sand fly season ( | |||
|---|---|---|---|---|
| rSP03B | rSP03B + rSP01 | SGH | Start, | End, |
| − | − | − | 29 (13.9) | 10 (4.8) |
| − | − | + | 5 (2.4) | 5 (2.4) |
| − | + | − | 16 (7.7) | 6 (2.9) |
| + | − | − | 0 (0) | 2 (1.0) |
| − | + | + | 29 (13.9) | 9 (4.3) |
| + | − | + | 0 (0) | 1 (0.5) |
| + | + | − | 8 (3.8) | 8 (3.8) |
| + | + | + | 121 (58.2) | 167 (80.3) |
Abbreviations: rSP03B, 43 KDa yellow-related protein; rSP03B + rSP01, rSP03B and 35.5 kDa apyrase; SGH, salivary gland homogenate
Agreement rates between diagnostic tests results at the beginning and end of the sand fly season
| Comparison | Sand fly season | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Start | End | |||||||||||
| Kappa | 95% CI | PA (%) | NA (%) | OA (%) | Kappa | 95% CI | PA (%) | NA (%) | OA (%) | |||
| A | 0.002 | 0.671 | 0.501–0.842 | 70.0 | 98.8 | 94.2 | 0.016 | 0.747 | 0.605–0.888 | 77.6 | 97.0 | 94.7 |
| A | < 0.001 | 0.075 | − 0.031–0.181 | 25.2 | 72.8 | 60.1 | 0.041 | 0.019 | − 0.115–0.153 | 18.7 | 82.1 | 70.7 |
| A | < 0.001 | − 0.026 | − 0.138–0.087 | 17.8 | 73.7 | 60.1 | ||||||
| A | < 0.001 | 0.014 | − 0.059–0.009 | 21.9 | 53.6 | 41.2 | < 0.001 | 0.002 | − 0.041–0.045 | 24.2 | 24.9 | 24.5 |
| A | < 0.001 | 0.029 | − 0.007–0.064 | 24.0 | 29.6 | 26.9 | < 0.001 | − 0.018 | − 0.058–0.022 | 22.8 | 14.2 | 18.8 |
| A | < 0.001 | 0.037 | − 0.014–0.088 | 24.3 | 41.7 | 34.1 | < 0.001 | 0.008 | − 0.030–0.046 | 35.3 | 24.6 | 23.6 |
| B | < 0.001 | 0.006 | − 0.074–0.089 | 12.2 | 72.6 | 58.2 | < 0.001 | 0.055 | − 0.078–0.188 | 18.2 | 84.6 | 74.0 |
| B | < 0.001 | − 0.049 | − 0.144–0.046 | 10.9 | 74.7 | 60.6 | ||||||
| B | < 0.001 | 0.021 | − 0.031–0.073 | 14.0 | 55.0 | 40.9 | < 0.001 | − 0.001 | − 0.038–0.035 | 17.2 | 24.8 | 21.2 |
| B | < 0.001 | 0.016 | − 0.009–0.040 | 13.8 | 29.0 | 22.1 | < 0.001 | 0.008 | − 0.014–0.030 | 18.1 | 16.5 | 17.3 |
| B | < 0.001 | 0.008 | − 0.032–0.047 | 13.0 | 40.5 | 29.3 | < 0.001 | 0.018 | − 0.007–0.043 | 18.8 | 23.4 | 21.2 |
| C | 0.007 | 0.002 | − 0.132–0.132 | 27.1 | 71.1 | 58.7 | ||||||
| C | < 0.001 | 0.079 | − 0.044–0.202 | 53.3 | 50.5 | 51.9 | < 0.001 | − 0.060 | − 0.128–0.008 | 31.3 | 19.8 | 26.0 |
| C | < 0.001 | 0.015 | − 0.072–0.103 | 55.6 | 26.8 | 44.7 | < 0.001 | − 0.013 | − 0.060–0.034 | 34.8 | 14.4 | 26.0 |
| C | < 0.001 | 0.010 | − 0.004–0.204 | 57.5 | 42.1 | 51.0 | < 0.001 | − 0.031 | − 0.089–0.028 | 33.3 | 19.2 | 26.9 |
| D | < 0.001 | 0.022 | − 0.051–0.095 | 50.4 | 25.3 | 40.4 | ||||||
| D | < 0.001 | − 0.058 | − 0.123–0.008 | 47.3 | 10.4 | 33.7 | ||||||
| D | < 0.001 | − 0.031 | − 0.104–0.041 | 48.0 | 18.5 | 36.5 | ||||||
| E | < 0.001 | 0.484 | 0.369–0.598 | 85.2 | 60.2 | 78.4 | 0.010 | 0.580 | 0.408–0.752 | 95.1 | 62.5 | 91.4 |
| E | < 0.001 | 0.542 | 0.425–0.660 | 85.2 | 68.2 | 79.8 | 0.540 | 0.505 | 0.334–0.677 | 93.3 | 54.1 | 88.5 |
| F | < 0.001 | 0.584 | 0.451–0.716 | 91.2 | 66.7 | 86.1 | 0.118 | 0.494 | 0.304–0.684 | 94.6 | 54.6 | 90.4 |
aLeishmania DNA was not detected at the beginning of the phlebotomine sand fly season by conjunctival swab PCR
Abbreviations: A, enzyme-linked immunosorbent assay; B, immunofluorescence antibody test; C, peripheral blood-polymerase chain reaction (PCR); D, conjunctival swab-PCR; E, 43 KDa yellow-related protein; F, 43 kDa yellow-related protein and 35.5 kDa apyrase; G, salivary gland homogenate; PA, positive agreement; NA, negative agreement; OA, overall agreement